Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 318-326

  Cao, Xuebing ^a   Liang, Li ^a   Hadcock, John R ^c   Iredale, Philip A ^c   Griffith, David A ^c   Menniti, Frank S ^c   Factor, Stewart ^a   Greenamyre, J Timothy ^b   Papa, Stella M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (2 CHLOROPHENYL) 8 (4 CHLOROPHENYL) 2 METHYLPYRAZOLO[1,5 A][1,3,5] TRIAZIN 4 YL] 3 ETHYLAMINOAZETIDINE 3 CARBOXYLIC ACID AMIDE BENZENESULFONATE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID; BENSERAZIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CARBIDOPA PLUS LEVODOPA; GLUTAMIC ACID; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ELECTROCHEMISTRY; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MONOTHERAPY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; RHESUS MONKEY; TREATMENT RESPONSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; AZETIDINES; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA MULATTA; MALE; MOLECULAR STRUCTURE; PARKINSON DISEASE; RECEPTOR, CANNABINOID, CB1; TRIAZINES;

EID: 34548848043     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.125666     Document Type: Article

References (42)

1. Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, and Hadcock JR (1996) Identification and characterization of novel somatostatin antagonists. Mol Pharmacol 50:709-715.
2. Blandini F, Martignoni E, Pacchetti C, Desideri S, Rivellini D, and Nappi G (1997) Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 700:278-282.
3. Brotchie JM (1998) Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 13:871-876.
4. Brown TM, Brotchie JM, and Fitzjohn SM (2003) Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci 23:11073-11077.
5. Chase TN and Oh JD (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47:S122-S129; discussion S129-S130.
6. Di Marzo V, Hill MP, Bisogno T, Crossman AR, and Brotchie JM (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432-1438.
7. Di Marzo V, Melck D, Bisogno T, and De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521-528.
8. Fernandez-Espejo E, Caraballo I, de Fonseca FR, El Banoua F, Ferrer B, Flores JA, and Galan-Rodriguez B (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18:591-601.
9. Ferrer B, Asbrock N, Kathuria S, Piomelli D, and Giuffrida A (2003) Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18:1607-1614.
10. Fox SH, Henry B, Hill M, Crossman A, and Brotchie J (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 17:1180-1187.
11. Gerdeman G and Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468-471.
12. Gerdeman GL, Ronesi J, and Lovinger DM (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5:446-451.
13. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, and Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
14. Griffith DA (2007), Inventor; Pfizer, Inc., assignee. Cannabinoid receptor ligands and uses thereof. U.S. Patent 7,176,210. 2007 Feb 13.
15. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, and Kase H (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-1677.
16. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agro A, and Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900-6907.
17. Hardman CD, Henderson JM, Finkelstein DI, Horne MK, Paxinos G, and Halliday GM (2002) Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J Comp Neurol 445:238-255.
18. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932-1936.
19. Hermann H, Marsicano G, and Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109:451-460.
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
21. Kreitzer AC and Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445:643-647.
22. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, and Fernandez-Ruiz JJ (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827-1832.
23. Little PJ, Compton DR, Johnson MR, Melvin LS, and Martin BR (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247:1046-1051.
24. Mailleux P and Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61:1705-1712.
25. Maneuf YP, Nash JE, Crossman AR, and Brotchie JM (1996) Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308:161-164.
26. Meschler JP, Clarkson FA, Mathews PJ, Howlett AC, and Madras BK (2000a) D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates. J Pharmacol Exp Ther 292:952-959.
27. Meschler JP, Conley TJ, and Howlett AC (2000b) Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol Biochem Behav 67:567-573.
28. Meschler JP, Howlett AC, and Madras BK (2001) Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology 156:79-85.
29. Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, Le Fur G, Damier P, Welter ML, and Agid Y (2004) Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 27:108-110.
30. Morelli M, Fenu S, Carta A, and Di Chiara G (1996) Effect of MK 801 on priming of D1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen. Behav Brain Res 79:93-100.
31. Nutt JG (2000) Clinical pharmacology of levodopa-induced dyskinesia. Ann Neurol 47:S160-S164; discussion S164-S166.
32. Nutt JG (2001) Fluctuations in response to treatment for Parkinson's disease. Adv Neurol 86:361-366.
33. Nutt JG and Holford NH (1996) The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39:561-573.
34. Obeso JA, Olanow CW, and Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23:S2-S7.
35. Papa SM, Auberson YP, and Greenamyre JT (2004) Prolongation of levodopa responses by glycine B antagonists in parkinsonian primates. Ann Neurol 56:723-727.
36. Papa SM and Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574-578.
37. Pearce RK, Jackson M, Smith L, Jenner P, and Marsden CD (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 10:731-740.
38. Romero J, Berrendero F, Perez-Rosado A, Manzanares J, Rojo A, Fernandez-Ruiz JJ, de Yebenes JG, and Ramos JA (2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 66:485-494.
39. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, and Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108-2111.
40. Szabo B, Wallmichrath I, Mathonia P, and Pfreundtner C (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97:89-97.
41. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, and Brotchie JM (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 19:1140-1142.
42. Wallmichrath I and Szabo B (2002) Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113:671-682.